Ensuring patient safety in clinical trials for treatment of acute stroke

JAMA. 2001 Dec 5;286(21):2718-9. doi: 10.1001/jama.286.21.2718.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Clinical Trials as Topic / standards*
  • Fibrinolytic Agents / adverse effects
  • Fibrinolytic Agents / therapeutic use
  • Guanidines / adverse effects
  • Guanidines / therapeutic use
  • Humans
  • Neuroprotective Agents / adverse effects
  • Neuroprotective Agents / therapeutic use*
  • Risk
  • Stroke / drug therapy*
  • Thrombolytic Therapy
  • Tissue Plasminogen Activator / adverse effects
  • Tissue Plasminogen Activator / therapeutic use

Substances

  • Fibrinolytic Agents
  • Guanidines
  • Neuroprotective Agents
  • aptiganel
  • Tissue Plasminogen Activator